Furthermore, in vivo and in vitro experiments confirmed that miR-93-5p upregulation inhibited CRC proliferation and invasion, while the compensation experiments confirmed that CTBP1-AS2 upregulation inhibited miR-93-5p and promoted tumor progression, indicating that miR-93-5p was a negative regulator of CRC progression. This evidence concerns the gene CTBP1 and neoplasm.